The correlation of serum S100A8 level and the prognosis in patients with community-acquired pneumonia

JIANG Ya-lin; FU Lin; ZHAO Hui

doi:10.16462/j.cnki.zhjbkz.2022.08.016

Volume 26 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2022 > 26(8): 967-973

JIANG Ya-lin, FU Lin, ZHAO Hui. The correlation of serum S100A8 level and the prognosis in patients with community-acquired pneumonia[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(8): 967-973. doi: 10.16462/j.cnki.zhjbkz.2022.08.016

Citation:

JIANG Ya-lin, FU Lin, ZHAO Hui. The correlation of serum S100A8 level and the prognosis in patients with community-acquired pneumonia[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(8): 967-973. doi: 10.16462/j.cnki.zhjbkz.2022.08.016

Citation:

PDF( 1705 KB)

The correlation of serum S100A8 level and the prognosis in patients with community-acquired pneumonia

doi: 10.16462/j.cnki.zhjbkz.2022.08.016

JIANG Ya-lin¹,
FU Lin^{2
,
,},
ZHAO Hui^{2
,
,}

1.
Pulmonary and Critical Care Medicine, The Bozhou People's Hospital, Bozhou 236800, China
2.
Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei 230032, China

Funds:

National Natural Science Foundation Incubation Program of the Second Affiliated Hospital of Anhui Medical University 2020GQFY05

The Scientific Research of Health Commission in Anhui Province AHWJ2021b091

More Information

Corresponding author: FU Lin, E-mail: fulindev@126.com; ZHAO Hui, E-mail: zhaohuichenxi@126.com
Received Date: 2021-03-24
Rev Recd Date: 2021-05-26

Available Online: 2022-08-23

Publish Date: 2022-08-10

Abstract

Abstract

Objective To explore the correlation between serum S100A8 on admission and the prognosis in patients with community-acquired pneumonia (CAP) as well as the potential risk factors of S100A8 elevation. Methods CAP patients were enrolled from December 2018 to December 2020 in the Department of Respiratory and Critical Care Medicine of Bozhou People's Hospital. Demographic characteristics and clinical information were extracted. Serum samples were collected. The levels of S100A8 and inflammatory cytokines were measured using enzyme-linked immunosorbent assay. Results All 100 patients with CAP were enrolled. The hospital stay was increased in parallel with serum S100A8 on admission among CAP patients (F=23.562, P=0.005). In addition, 10 patients with CAP died during hospitalization. Serum S100A8 level was higher in dead patients than those in alive cases (t=4.352, P=0.004). Moreover, logistic regression analysis found that serum S100A8 elevation was the risk factor of hospital stay prolonging (OR=3.111, 95% CI: 1.112-8.702, P=0.031) and mortality elevation (OR=1.214, 95% CI: 1.058-1.562, P=0.022) in CAP patients. Additionally, Pearson correlation analysis found that S100A8 level was associated with inflammatory cytokines. Further logistic regression analysis found that age (OR=1.230, 95% CI: 1.030-1.528, P=0.044), high systolic pressure (OR=1.155, 95% CI: 1.011-1.320, P=0.033) and comorbidity with renal disease (OR=2.541, 95% CI: 1.578-6.537, P=0.038) were independent risk factors of S100A8 elevation among CAP patients. Conclusions Serum S100A8 level on admission is positively correlated with adverse prognosis in CAP patients. Serum S100A8 is more prone to elevating in older and higher blood pressure patients with renal disease. Consequently, S100A8 may be used as an early serum biomarker of prognosis for CAP patients.
- Community-acquired pneumonia,
- S100A8,
- Hospital stay,
- Death risk,
- Inflammation

FullText(HTML)

References(19)

References

[1]	Franco J. Community-acquired pneumonia[J]. Radiol Technol, 2017, 88(6): 621-636.
[2]	Bartlett JG, Mundy LM. Community-acquired pneumonia[J]. N Engl J Med, 1995, 333(24): 1618-1624. DOI: 10.1056/nejm199512143332408.
[3]	Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009[J]. Thorax, 2009, 64(Suppl 3): iii1-iii55. DOI: 10.1136/thx.2009.121434.
[4]	Ferreira-Coimbra J, Sarda C, Rello J. Burden of community-acquired pneumonia and unmet clinical needs[J]. Adv Ther, 2020, 37(4): 1302-1318. DOI: 10.1007/s12325-020-01248-7.
[5]	He GY, Zhao CH, Wu DG, et al. S100A8 promotes inflammation via toll-like receptor 4 after experimental traumatic brain injury[J]. Front Neurosci, 2020, 14: 616559. DOI: 10.3389/fnins.2020.616559.
[6]	Xiao X, Yang C, Qu SL, et al. S100 proteins in atherosclerosis[J]. Clin Chim Acta, 2020, 502: 293-304. DOI: 10.1016/j.cca.2019.11.019.
[7]	Boyd JH, Kan B, Roberts H, et al. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products[J]. Circ Res, 2008, 102(10): 1239-1246. DOI: 10.1161/CIRCRESAHA.107.167544.
[8]	Ruan G, Xu J, Wang K, et al. Associations between serum S100A8/S100A9 and knee symptoms, joint structures and cartilage enzymes in patients with knee osteoarthritis[J]. Osteoarthritis Cartilage, 2019, 27(1): 99-105. DOI: 10.1016/j.joca.2018.08.020.
[9]	Azramezani Kopi T, Amini Kadijani A, Parsian H, et al. The value of mRNA expression of S100A8 and S100A9 as blood-based biomarkers of inflammatory bowel disease[J]. Arab J Gastroenterol, 2019, 20(3): 135-140. DOI: 10.1016/j.ajg.2019.07.002.
[10]	Huang XL, Tan XY, Liang Y, et al. Differential DAMP release was observed in the sputum of COPD, asthma and asthma-COPD overlap (ACO) patients[J]. Sci Rep, 2019, 9(1): 19241. DOI: 10.1038/s41598-019-55502-2.
[11]	Raquil MA, Anceriz N, Rouleau P, et al. Blockade of antimicrobial proteins S100A8 and S100A9 inhibits phagocyte migration to the alveoli in streptococcal pneumonia[J]. J Immunol, 2008, 180(5): 3366-3374. DOI: 10.4049/jimmunol.180.5.3366.
[12]	Unamuno X, Gómez-Ambrosi J, Ramírez B, et al. NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling[J]. Cell Mol Immunol, 2021, 18(4): 1045-1057. DOI: 10.1038/s41423-019-0296-z.
[13]	Fujita Y, Khateb A, Li Y, et al. Regulation of S100A8 stability by RNF5 in intestinal epithelial cells determines intestinal inflammation and severity of colitis[J]. Cell Rep, 2018, 24(12): 3296-3311.e6. DOI: 10.1016/j.celrep.2018.08.057.
[14]	Zheng L, Fei J, Feng CM, et al. Serum 8-iso-PGF2α predicts the severity and prognosis in patients with community-acquired pneumonia: a retrospective cohort study[J]. Front Med (Lausanne), 2021, 8: 633442. DOI: 10.3389/fmed.2021.633442.
[15]	Liu HY, Xiang HX, Xiang Y, et al. The associations of serum S100A9 with the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study[J]. BMC Infect Dis, 2021, 21(1): 327. DOI: 10.1186/s12879-021-06020-y.
[16]	Huang YK, Liu AH, Liang L, et al. Diagnostic value of blood parameters for community-acquired pneumonia[J]. Int Immunopharmacol, 2018, 64: 10-15. DOI: 10.1016/j.intimp.2018.08.022.
[17]	傅利军, 黄朝辉, 屠春雨, 等. 儿童社区获得性肺炎住院时间的影响因素分析[J]. 中华疾病控制杂志, 2015, 19(1): 99-101. DOI: 10.16462/j.cnki.zhjbkz.2015.01.030. Fu LJ, Huang ZH, Tu CY, et al. Factors associated with duration of hospital stays in community acquired pneumonia of children[J]. Chin J Dis Control Prev, 2015, 19(1): 99-101. DOI: 10.16462/j.cnki.zhjbkz.2015.01.030.
[18]	Fu L, Li XY, Fei J, et al. Myocardial injury at early stage and its association with the risk of death in COVID-19 patients: a hospital-based retrospective cohort study[J]. Front Cardiovasc Med, 2020, 7: 590688. DOI: 10.3389/fcvm.2020.590688.
[19]	Fu L, Fei J, Xu S, et al. Liver dysfunction and its association with the risk of death in COVID-19 patients: a prospective cohort study[J]. J Clin Transl Hepatol, 2020, 8(3): 246-254. DOI: 10.14218/JCTH.2020.00043.